脊髓小腦萎縮症第十七型 (SCA17) 是一種多麩胺酸造成的神經退化性疾病，是由於在TATA-box binding蛋白基因 (TBP基因) 上有不正常的CAG三核甘酸的擴增，造成TBP蛋白不正常摺疊並聚集在細胞當中，進而產生毒性。在SCA17的病徵上，目前有發現到有運動能力失調、運動功能障礙、認知功能失常等情形。TBP的主要功能是在細胞中啟動轉錄功能，組蛋白去乙醯化酶抑制劑 (HDACi) 可促使基因進行轉錄，因此被引用當作治療SCA17的藥物有其潛力。我們測試了多種HDACi化合物，當中發現LBH589可以在SCA17小腦組織培養上有效地降低TBP蛋白的聚集，然而在活體的實驗上發現LBH589不能有效改善SCA17運動失調的現象。此外，小鼠的食慾以及中樞神經系統發育可能會受到LBH589刺激而造成遲緩。因此，目前我們的活體實驗證據並無法說明LBH589對SCA17之治療是有幫助的。

Spinocerebellar ataxia type 17 (SCA17) is a polyQ neurodegenerative disease caused by abnormal CAG repeat expansion of TATA-box binding protein (TBP) gene. The CAG trinucleotide expansion results in the mutant polyQ TBP protein misfolded and accumulated in the cells, which further caused the neuronal lose, especially the cerebellar Purkinje cells. Ataxia, motor dysfunction, and dementia are clinical symptoms of SCA17. As the role of TBP being critical in transcription initiation, improving the transcriptional activity by histone deacetylase inhibitors (HDACi) becomes an attractive approach for SCA17 treatment. We have screened several HDACi compounds and found that LBH589 could significantly reduce the TBP aggregation on SCA17 cerebellar slice culture. In in vivo study, we found LBH589 couldn’t ameliorate the motor function and the pathology of SCA17 mice. Additionally, the appetite of mice was reduced and the central nervous system was impacted by LBH589 treatment. We could not suggest that LBH589 is potential in SCA17 treatment from our in vivo results.

Abou-Sleymane G, Chalmel F, Helmlinger D, Lardenois A, Thibault C, Weber C, Merienne K, Mandel JL, Poch O, Devys D, Trottier Y. 2006. Polyglutamine expansion causes neurodegeneration by altering the neuronal differentiation program. Hum Mol Genet 15:691-703.
Bickler PE, Fahlman CS. 2009. Expression of signal transduction genes differs after hypoxic or isoflurane preconditioning of rat hippocampal slice cultures. Anesthesiology 111:258-266.
Birgbauer E, Rao TS, Webb M. 2004. Lysolecithin induces demyelination in vitro in a cerebellar slice culture system. J Neurosci Res 78:157-166.
Cendelin J, Voller J, Vozeh F. 2010. Ataxic gait analysis in a mouse model of the olivocerebellar degeneration. Behav Brain Res 210:8-15.
Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL, Hsiao PW. 2009. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 15:840-850.
Chang YC, Lin CY, Hsu CM, Lin HC, Chen YH, Lee-Chen GJ, Su MT, Ro LS, Chen CM, Hsieh-Li HM. 2011. Neuroprotective effects of granulocyte-colony stimulating factor in a novel transgenic mouse model of SCA17. J Neurochem 118:288-303.
Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. 2009. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32:591-601.
Clive S, Woo MM, Nydam T, Kelly L, Squier M, Kagan M. 2012. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 70:513-522.
Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM. 2009. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 8:2221-2231.
Davids E, Hevers W, Damgen K, Zhang K, Tarazi FI, Luddens H. 2002. Organotypic rat cerebellar slice culture as a model to analyze the molecular pharmacology of GABAA receptors. Eur Neuropsychopharmacol 12:201-208.
do Nascimento AL, Dos Santos NF, Campos Pelagio F, Aparecida Teixeira S, de Moraes Ferrari EA, Langone F. 2012. Neuronal degeneration and gliosis time-course in the mouse hippocampal formation after pilocarpine-induced status epilepticus. Brain Res 1470:98-110.
Dokmanovic M, Clarke C, Marks PA. 2007. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981-989.
Duennwald ML. 2011. Polyglutamine misfolding in yeast: toxic and protective aggregation. Prion 5:285-290.
Duncan C, Papanikolaou T, Ellerby LM. 2010. Autophagy: polyQ toxic fragment turnover. Autophagy 6:312-314.
Dusart I, Airaksinen MS, Sotelo C. 1997. Purkinje cell survival and axonal regeneration are age dependent: an in vitro study. J Neurosci 17:3710-3726.
Eilam D. 2003. Open-field behavior withstands drastic changes in arena size. Behav Brain Res 142:53-62.
El Idrissi A, Boukarrou L, Heany W, Malliaros G, Sangdee C, Neuwirth L. 2009. Effects of taurine on anxiety-like and locomotor behavior of mice. Adv Exp Med Biol 643:207-215.
Fischer A, Sananbenesi F, Mungenast A, Tsai LH. 2010. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 31:605-617.
Friedlander RM. 2003. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348:1365-1375.
Friedman MJ, Shah AG, Fang ZH, Ward EG, Warren ST, Li S, Li XJ. 2007. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci 10:1519-1528.
Fujita Y, Morinobu S, Takei S, Fuchikami M, Matsumoto T, Yamamoto S, Yamawaki S. 2012. Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. J Psychiatr Res 46:635-643.
Gao Z, van Beugen BJ, De Zeeuw CI. 2012. Distributed synergistic plasticity and cerebellar learning. Nat Rev Neurosci 13:619-635.
Garbes L, Riessland M, Holker I, Heller R, Hauke J, Trankle C, Coras R, Blumcke I, Hahnen E, Wirth B. 2009. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 18:3645-3658.
Hashimoto M, Hibi M. 2012. Development and evolution of cerebellar neural circuits. Dev Growth Differ 54:373-389.
He M, Zhang B, Wei X, Wang Z, Fan B, Du P, Zhang Y, Jian W, Chen L, Wang L, Fang H, Li X, Wang PA, Yi F. 2013. HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury. J Cell Mol Med.
Igelstrom KM, Shirley CH, Heyward PM. 2011. Low-magnesium medium induces epileptiform activity in mouse olfactory bulb slices. J Neurophysiol 106:2593-2605.
Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA. 2012. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis 46:351-361.
Kapfhammer JP. 2004. Cellular and molecular control of dendritic growth and development of cerebellar Purkinje cells. Prog Histochem Cytochem 39:131-182.
Kawai Y, Suenaga M, Watanabe H, Sobue G. 2009. Cognitive impairment in spinocerebellar degeneration. Eur Neurol 61:257-268.
Kobayashi H, Abe K, Matsuura T, Ikeda Y, Hitomi T, Akechi Y, Habu T, Liu W, Okuda H, Koizumi A. 2011. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet 89:121-130.
Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, Saito M, Yamada M, Takahashi H, Tsuji S. 1999. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet 8:2047-2053.
Lafarga M, Andres MA, Calle E, Berciano MT. 1998. Reactive gliosis of immature Bergmann glia and microglial cell activation in response to cell death of granule cell precursors induced by methylazoxymethanol treatment in developing rat cerebellum. Anat Embryol (Berl) 198:111-122.
Lee SC, Cheong HJ, Kim SJ, Yoon J, Kim HJ, Kim KH, Kim SH, Kim HJ, Bae SB, Kim CK, Lee N, Lee KT, Park SK, Hong DS, Park HS, Won JH. 2011. Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines. Anticancer Res 31:3385-3394.
Lee SJ, Lim HS, Masliah E, Lee HJ. 2011. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 70:339-348.
Lemoine M, Younes A. 2010. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 10:462-470.
Lonchamp E, Dupont JL, Beekenkamp H, Poulain B, Bossu JL. 2006. The mouse cerebellar cortex in organotypic slice cultures: an in vitro model to analyze the consequences of mutations and pathologies on neuronal survival, development, and function. Crit Rev Neurobiol 18:179-186.
Lordkipanidze T, Dunaevsky A. 2005. Purkinje cell dendrites grow in alignment with Bergmann glia. Glia 51:229-234.
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. 2001. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202.
Markvartova V, Cendelin J, Vozeh F. 2010. Changes of motor abilities during ontogenetic development in Lurcher mutant mice. Neuroscience 168:646-651.
Masino L. 2004. Polyglutamine and neurodegeneration: structural aspects. Protein Pept Lett 11:239-248.
McCampbell A, Fischbeck KH. 2001. Polyglutamine and CBP: fatal attraction? Nat Med 7:528-530.
Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. 2005. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16:4623-4635.
Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP. 2011. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 6:e27746.
Miyata T, Saito K, Nishizawa Y, Murayama A, Masaoka M, Ogawa M. 2005. Modern slice culture for direct observation of production and migration of brain neurons. Nagoya J Med Sci 67:65-70.
Narita K, Kikuchi T, Watanabe K, Takizawa T, Oguchi T, Kudo K, Matsuhara K, Abe H, Yamori T, Yoshida M, Katoh T. 2009. Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chemistry 15:11174-11186.
Neri P, Bahlis NJ, Lonial S. 2012. Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs 21:733-747.
Noraberg J, Poulsen FR, Blaabjerg M, Kristensen BW, Bonde C, Montero M, Meyer M, Gramsbergen JB, Zimmer J. 2005. Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. Curr Drug Targets CNS Neurol Disord 4:435-452.
Orr HT. 2012. Polyglutamine neurodegeneration: expanded glutamines enhance native functions. Curr Opin Genet Dev 22:251-255.
Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, Farley N, Helquist P, Wiest O, Maxfield FR. 2011. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A 108:5620-5625.
Popiel HA, Nagai Y, Fujikake N, Toda T. 2007. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo. Mol Ther 15:303-309.
Prut L, Belzung C. 2003. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463:3-33.
Riessland M, Brichta L, Hahnen E, Wirth B. 2006. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 120:101-110.
Robinson R. 2006. Polyglutamine leads to altered chromatin architecture and neurodegeneration. PLoS Biol 4:e70.
Sierra C, Coca A, Schiffrin EL. 2011. Vascular mechanisms in the pathogenesis of stroke. Curr Hypertens Rep 13:200-207.
Slemmer JE, Haasdijk ED, Engel DC, Plesnila N, Weber JT. 2007. Aldolase C-positive cerebellar Purkinje cells are resistant to delayed death after cerebral trauma and AMPA-mediated excitotoxicity. Eur J Neurosci 26:649-656.
Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, Xu Y, Tsutusmi-Ishii Y, Miyake K, Miyake N, Kondo S, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. 2007. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ 14:1443-1456.
Witter DJ, Harrington P, Wilson KJ, Chenard M, Fleming JC, Haines B, Kral AM, Secrist JP, Miller TA. 2008. Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2). Bioorg Med Chem Lett 18:726-731.
Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA, Schimmer AD. 2010. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther 9:246-256.
Yeh HH, Young D, Gelovani JG, Robinson A, Davidson Y, Herholz K, Mann DM. 2013. Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease. Brain Res 1504:16-24.
Yi J, Zhang L, Tang B, Han W, Zhou Y, Chen Z, Jia D, Jiang H. 2013. Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4. PLoS One 8:e54792.
Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. 2003. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 23:2193-2202.
Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R. 2001. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci U S A 98:1982-1987.